Cerulean Closes Public Offering of Common Stock

CAMBRIDGE, Mass.--Cerulean Pharma Inc. (Nasdaq: CERU) today announced the closing of its underwritten public offering of 6,716,000 shares of common stock, including 876,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $6.00 per share. The gross proceeds to Cerulean from this offering were approximately $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Cerulean.

Leerink Partners LLC and Barclays Capital Inc. acted as joint book-running managers for the offering. Canaccord Genuity Inc., JMP Securities LLC and Wedbush PacGrow acted as co-managers for the offering.

A registration statement on Form S-1 relating to these securities was declared effective by the Securities and Exchange Commission on April 6, 2015.

The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by phone at (800) 808‐7525, ext. 6142 or from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, NY 11717, by calling toll-free (888) 603-5847 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor TargetingTM Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.

 

Contacts

Cerulean Pharma Inc.
Aurora Krause, 617-551-9627
Corporate Communications
[email protected]

 

Suggested Articles

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.

Lilly commited $820 million in development milestones for the chance to work with Sitryx on drugs that manipulate intracellular metabolic pathways.